Skip to content

Study · In vitro (cells) · 2013

1 result

Three novel human sporadic melanoma cell lines: signaling pathways controlled by MC1R, BRAF and β-catenins.

Zanna P, Maida I, Grieco C, Guida S, Turpin Sevilla MC, De Summa S, Tommasi S, Vena GA, Filotico R, Guida G

Journal of biological regulators and homeostatic agents1 Jan 2013Cited by 17 (Europe PMC)

PMID23489693 (opens in a new tab)PepBankPUB-23489693
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In three novel human melanoma cell lines with BRAF mutations, cells were unresponsive to NDP-MSH treatment.

    In plain wordsIn cells from three new human melanoma lines, NDP-MSH treatment did not produce a response.

    Peptide
    Melanotan I (afamelanotide)
    Outcome
    No significant changeResponse to NDP-MSH treatment in new melanoma cell lines
    Study

    humann: not reported in source

    Human melanoma cell lines hmel1, hmel9, hmel11
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Our new melanoma cell lines were BRAF mutated in hetero- and homozygosis, even with a wild type MC1R, and unresponsive to NDP-MSH treatment.
    1 context sentence
    Summary · context
    We studied the behaviour of three novel human sporadic melanoma cell lines (hmel1, hmel9, hmel11) extracted from tumors with different degrees of malignancy, concerning the cell signalling pathways controlled by MC1R, BRAF, NRAS and β-catenins.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.